Harrow, a leading North American eyecare pharmaceutical company, has obtained approval from the Centers for Medicare & Medicaid Services (CMS) for a transitional pass-through reimbursement status for its product TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL. This approval, effective April 1, 2025, extends TRIESENCE’s reimbursement eligibility beyond eyecare professionals’ offices to include Ambulatory Surgery Centers (ASC) and Hospital Outpatient Departments (HOPD), solidifying its unique market position.
Expanded Reimbursement Enhances Market Access
With the CMS approval, TRIESENCE will be eligible for separate reimbursement outside of the surgical bundled payment in both ASC and HOPD settings for the next three years. Previously, the issuance of a permanent, product-specific J‑Code (J3300) facilitated its reimbursement in eyecare professionals’ offices. This new status makes TRIESENCE the sole preservative-free synthetic corticosteroid accessible with separate reimbursement across all traditional care environments, enhancing its versatility and reach within the medical community.
Harrow’s Commitment to Patient Care
Mark L. Baum, Chairman and CEO of Harrow, expressed gratitude for the CMS decision, highlighting the company’s investment in restoring TRIESENCE’s supply chain. This move ensures that ophthalmologists, including retina specialists, can confidently administer an FDA-approved, preservative-free treatment, replacing more hazardous off-label alternatives that were previously necessary due to TRIESENCE’s unavailability.
– TRIESENCE’s inclusion in ASCs and HOPDs is likely to boost its adoption among diverse healthcare providers.
– The reimbursement approval may encourage other pharmaceutical companies to pursue similar pathways for their specialized treatments.
– Reliable supply chain management by Harrow reduces the risk of treatment gaps and enhances patient trust.
The reimbursement rate set by CMS at the Average Sales Price (ASP) plus 6% will facilitate broader access for Medicare beneficiaries, potentially leading to improved surgical outcomes and heightened patient safety across the nation. Harrow’s strategic positioning ensures that TRIESENCE remains a preferred choice for treating ocular inflammatory conditions and during vitrectomy procedures.
Beyond the immediate financial implications, this approval underscores Harrow’s dedication to advancing ophthalmic care. By ensuring that TRIESENCE is readily available in key healthcare settings, the company not only supports ophthalmologists in delivering effective treatments but also contributes to overall public health by making essential medications more accessible and affordable.
Harrow continues to invest in research and development to expand its portfolio of innovative ophthalmic solutions. The company’s proactive approach in securing reimbursement statuses reflects its commitment to addressing the evolving needs of eyecare professionals and their patients, positioning Harrow as a pivotal player in the ophthalmology pharmaceutical landscape.
Ensuring that essential treatments like TRIESENCE are reimbursed appropriately across various care settings not only benefits medical practitioners but also enhances patient outcomes by providing reliable and effective treatment options. Harrow’s successful navigation of the CMS approval process sets a benchmark for excellence and dedication in the competitive pharmaceutical industry.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
